<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02537509</url>
  </required_header>
  <id_info>
    <org_study_id>2015-000881-73</org_study_id>
    <secondary_id>35RC14_9754_PRADA</secondary_id>
    <nct_id>NCT02537509</nct_id>
  </id_info>
  <brief_title>PRAgmatic Trial in Atopic Dermatitis Testing Long-term Control Effectiveness of New Phototherapy Regimen During Winter Coupled With Oral Vitamin D Supplementation vs. Placebo</brief_title>
  <acronym>PRADA</acronym>
  <official_title>Multicentre, Cross-over, PRAgmatic Trial in Atopic Dermatitis Testing Long-term Control Effectiveness of New Phototherapy Regimen During Winter as an add-on Therapy, Coupled With Oral Vitamin D Supplementation vs. Placebo in a Randomised, Parallel-group Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Spaced phototherapy sessions during winter as add-on therapy in combination with vitamin D
      supplementation or not, could be beneficial to improve disease LTC in AD patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The major therapeutic challenge in patient with Atopic Dermatitis is long-term control of
      disease activity (LTC), for which the current TAT-based pro-active strategy does not meet all
      the needs.

      Phototherapy is a good candidate: it is widely used as a second-line treatment in AD with
      demonstrated efficacy. However, only short-term control has been evaluated; and only 2-3
      times a week intensive schedules have been tested and are used in current practice. A novel
      phototherapy regimen would be required for disease LTC, allowing a trade-off between disease
      control, UV-induced risks, and patient adherence.

      Vitamin D supplementation is another good candidate: several studies have shown lower serum
      levels of vitamin D to be correlated with more severe AD; and three short-term, low-power
      low-quality, placebo-controlled randomised trials testing vitamin D supplementation yielded
      conflicting results, leaving its therapeutic efficacy undecided for short-term control, and
      unknown for LTC.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 27, 2015</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hierarchical criterion based on repeated measures of PO-SCORAD severity score</measure>
    <time_frame>2 years</time_frame>
    <description>Measurement of PO-SCORAD score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hierarchical criterion based on cumulative consumption of topical anti-inflammatory treatments (collected tubes) during winter</measure>
    <time_frame>2 years</time_frame>
    <description>Measurement of cumulative consumption of topical anti-inflammatory treatments</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of desease severity</measure>
    <time_frame>2 years</time_frame>
    <description>Assessment of desease severity by EASI score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of desease severity</measure>
    <time_frame>2 years</time_frame>
    <description>Assessment of desease severity by IGA score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of desease severity</measure>
    <time_frame>2 years</time_frame>
    <description>Assessment of desease severity by SCORAD score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of desease severity</measure>
    <time_frame>2 years</time_frame>
    <description>Assessment of desease severity by POEM score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the quality of life</measure>
    <time_frame>2 years</time_frame>
    <description>Assessment of the quality of life by DLQI score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of serum Vitamin D (25-(OH)-vitamin D)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of total IgE serum</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessement of number of weeks of well-controlled atopic dermatitis</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of inter-visit cumulative consumption of topical anti-inflammatory treatments</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of patient satisfaction</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Cholecalciferol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of cholecalciferol every 3 months during 2 years combined with new phototherapy regimen during winter (phototherapy winter 1, observation winter 2 or the opposite)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo of cholecalciferol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administration of placebo of cholecalciferol every 3 months during 2 years combined with new phototherapy regimen during winter (phototherapy winter 1, observation winter 2 or the opposite)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <arm_group_label>Cholecalciferol</arm_group_label>
    <other_name>Uvedose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of cholecalciferol</intervention_name>
    <arm_group_label>Placebo of cholecalciferol</arm_group_label>
    <other_name>Placebo of Uvedose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with atopic dermatitis (Hanifin and Rajka criteria),

          -  Aged 15 years or more,

          -  With &gt; 2 years of disease evolution,

          -  With moderate-to-severe disease (IGA &gt; 2),

          -  Patients that have received TAT for at least 12 weeks and have symptoms requiring an
             increase in therapy,

          -  Seasonality in disease severity (based on a questionnaire assessing disease
             improvement during summer),

          -  Easy access to a phototherapy cabin (widely implanted in primary care dermatology
             private practice in France),

          -  Effective contraception to be used at least 30 days before initiation of treatment,
             during treatment and 29 weeks after last administration for women of reproductive age,

          -  Written informed consent of the patient

          -  For patients aged between 15 and 18, written informed consent of the parents and of
             the teenager.

        Exclusion Criteria:

          -  Any cause of contra-indication for vitamin D supplementation: flare of granulomatosis,
             primary hyperparathyroidism,

          -  Clinical suspicion of hypercalciuria,

          -  Indication to a systemic immunosuppressant in the next 2 years,

          -  Atopic dermatitis known to be aggravated by UV exposure,

          -  Any contra-indication for artificial or solar exposure including: genetic diseases
             with a predisposition to skin cancer, any history of personal skin cancer (melanoma,
             squamous cell skin cancer, basal cell skin cancer), lupus, dermatomyositis, any other
             photosensitizing skin disease, photosensitizing medication (see appendix 2),

          -  More than 100 previous phototherapy sessions in lifetime,

          -  Pregnancy or breastfeeding,

          -  Persons subject to major legal protection (safeguarding justice, guardianship,
             trusteeship), persons deprived of liberty.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine Droitcourt</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Catherine Droitcourt</last_name>
    <phone>+33 2 99 28 43 49</phone>
    <email>catherine.droitcourt@chu-rennes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie-Elodie Sarre</last_name>
      <phone>+33 2 41 35 34 19</phone>
      <email>marieelodie.sarre@chu-angers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint André</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julien Seneschal</last_name>
      <phone>+33 5 56 79 49 62</phone>
      <email>julien.seneschal@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Abasq</last_name>
      <email>claire.abasq@chu-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Femme-Mère-Enfant - Hospices Civils de Lyon</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alice Phan</last_name>
      <phone>+33 4 27 85 61 26</phone>
      <email>alice.phan@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Trousseau</name>
      <address>
        <city>Chambray Les Tours</city>
        <zip>37170</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuelle Le Bidre</last_name>
      <phone>+33 2 47 47 47 47 (7-1985)</phone>
      <email>emmanuelle_lb@yahoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHD Vendée</name>
      <address>
        <city>La Roche sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carole Poiraud</last_name>
      <phone>+33 2 51 44 61 83</phone>
      <email>carole.poiraud@chd-vendee.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corina Bara Passot</last_name>
      <phone>+33 2 44 71 07 50</phone>
      <email>cbara@ch-lemans.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Delphine Staumont-Sallé</last_name>
      <phone>+33 3 20 44 41 93</phone>
      <email>delphine.salle@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes - Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sébastien Barbarot</last_name>
      <phone>+33 2 40 08 40 86</phone>
      <email>sebastien.barbarot@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Perigueux</city>
        <zip>24000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cécile Javierre-Chabbert</last_name>
      <email>cchabbert@hotmail.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Laënnec</name>
      <address>
        <city>Quimper</city>
        <zip>29107</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrice Plantin</last_name>
      <phone>+33 2 90 94 41 16</phone>
      <email>p.plantin@ch-cornouaille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Droitcourt</last_name>
      <phone>+33 2 99 28 43 49</phone>
      <email>catherine.droitcourt@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Alain Dupuy</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henri Adamski</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHR St Brieuc</name>
      <address>
        <city>Saint Brieuc</city>
        <zip>22000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laure Darrieux</last_name>
      <phone>+33 2 96 01 74 66</phone>
      <email>laure.darrieux@ch-stbrieuc.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Valence</city>
        <zip>26000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>François Skowron</last_name>
      <phone>+33 4 75 75 75 49</phone>
      <email>fskowron@ch-valence.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Valenciennes</city>
        <zip>59322</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Weinborn</last_name>
      <phone>+33 3 27 17 50 58</phone>
      <email>weinborn-m@ch-valenciennes.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 28, 2015</study_first_submitted>
  <study_first_submitted_qc>August 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2015</study_first_posted>
  <last_update_submitted>October 12, 2017</last_update_submitted>
  <last_update_submitted_qc>October 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

